Written by the Nuvirox Research Team
Key points
- Several randomized, placebo-controlled trials have tested NADH (with and without CoQ10) in ME/CFS patients — more direct trial evidence than exists for almost any other condition in this series.
- Results are genuinely mixed: some trials found improved fatigue and quality-of-life scores; a larger 2021 trial found no significant difference from placebo.
- No effective, universally approved treatment for ME/CFS currently exists, which is exactly why researchers keep testing NAD+-related approaches.
Short answer: this is one of the better-studied conditions on this list, and the honest picture is genuinely mixed rather than clearly positive or negative. Multiple real trials exist; they don't all agree.
Why would NAD+ matter for ME/CFS?
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is characterized by profound, unexplained fatigue that isn't relieved by rest and worsens with exertion, often alongside unrefreshing sleep and cognitive difficulties. Mitochondrial dysfunction, impaired ATP synthesis, and CoQ10 deficiency have all been documented in ME/CFS patients, which is why NADH (the reduced, active form of NAD+) and CoQ10 — both central to mitochondrial energy production — have been repeated targets of ME/CFS clinical trials since the late 1990s.
What does the evidence actually show?
The earliest trial, by Forsyth and colleagues (1999), was a randomized, double-blind, placebo-controlled crossover study of oral NADH in 26 CFS patients and found therapeutic effects on CFS symptoms. Since then, a Spanish research group has run several trials combining CoQ10 (200 mg/day) with NADH (20 mg/day): an 8-week trial in 73 patients found improvements in fatigue and some biochemical parameters, and another 8-week trial in 80 patients found benefits on exercise heart-rate response along with fatigue, pain, and sleep measures. However, the largest and most recent trial — a 12-week study in 207 ME/CFS patients (2021) — found no statistically significant difference between CoQ10+NADH and placebo on its primary fatigue and quality-of-life endpoints.
Study snapshot: CoQ10 + NADH in ME/CFS (largest trial, 2021)
| Design | Randomized, double-blind, placebo-controlled |
| N | 207 patients |
| Duration | 12 weeks |
| Dose | 200 mg CoQ10 + 20 mg NADH daily vs. placebo |
| Finding | No significant difference from placebo on primary fatigue/QoL endpoints |
The honest counterweight
A comprehensive systematic review of randomized controlled trials in CFS/ME notes that CoQ10+NADH was one of only three pharmacological interventions to show statistical significance across dozens of RCTs reviewed — but also concludes plainly that "there was no definitely effective intervention with coherence and reproducibility" for ME/CFS overall. The largest, most recent, and arguably best-powered trial found no benefit. This is a case where earlier smaller positive trials didn't fully hold up as research scaled, which is a common and important pattern in medical research generally.
When to see a doctor
ME/CFS is a serious, often misunderstood and under-recognized condition, and post-exertional malaise (symptom worsening after exertion) means that exercise recommendations need to be individualized and cautious, unlike for most fatigue conditions. Diagnosis and management should involve a physician experienced with ME/CFS, since ruling out other causes of profound fatigue is an essential first step.
What's actually proven to help
Evidence-based management for ME/CFS emphasizes pacing (carefully managing activity to avoid post-exertional malaise), symptom-targeted treatment (for sleep, pain, orthostatic intolerance), and individualized care given how heterogeneous the condition is. No single supplement or medication has strong, consistent trial support as a cure or universal treatment.
How does ME/CFS research compare to other fatigue-related NAD+ studies?
ME/CFS shares research territory with broader fatigue topics covered in NAD+ and energy and with related severe-fatigue presentations discussed in burnout and chronic exhaustion — though it's important to note ME/CFS is a distinct, diagnosable medical condition, not simply severe everyday tiredness, and shouldn't be conflated with the more general fatigue content covered in why you might feel tired and unmotivated.
One additional trial worth knowing about: a separate 8-week randomized trial in 80 CFS patients specifically measured maximum heart rate during an exercise test as its primary endpoint (rather than self-reported fatigue alone), aiming for more objective physiological evidence of benefit alongside the subjective fatigue, pain, and sleep measures. This kind of objective-measure approach is exactly what researchers use to try to cut through the placebo-response challenges that plague fatigue-outcome trials generally, and it's part of why the field continues testing this combination despite the larger 2021 trial's null result — the objective and subjective findings across the full body of trials don't all point the same direction.
It's worth understanding why trial size matters so much here: the earliest positive trials involved 26, 73, and 80 patients respectively, while the trial finding no significant benefit involved 207 patients — roughly three times larger than the biggest earlier positive trial. Larger, better-powered trials are generally considered more reliable, which is part of why we're weighting the 2021 null result heavily in this summary rather than treating all four trials as equally persuasive.
If you do decide, with your physician's input, to try NADH or a CoQ10+NADH combination given the mixed-but-real trial history, it's worth setting a specific timeline (most positive trials showed effects within 8-12 weeks) and a specific symptom-tracking method before starting, so you can objectively evaluate whether it's helping in your specific case rather than relying on general impression alone.
A final honest note: ME/CFS research as a field has historically been underfunded relative to its disease burden, which is part of the broader context for why even the strongest available trials here (73-207 patients) are still considered small to moderate by the standards of major disease research, and why definitive answers on almost any ME/CFS intervention, including this one, have been slow to emerge.
Frequently asked questions
Do NADH supplements actually help chronic fatigue syndrome?
The trial evidence is mixed: some smaller trials found benefit, but the largest and most recent trial (207 patients) found no significant difference from placebo.
Is CoQ10 combined with NADH better than either alone?
That's the combination most trials have actually tested; standalone NADH has much less trial data of its own beyond the original 1999 study.
Should I try NADH for my chronic fatigue?
Given the mixed evidence, this is worth discussing with a physician familiar with ME/CFS management, especially to make sure any other treatable causes of fatigue have been ruled out first.
From Nuvirox
Why we formulated NAD+ Restore
To be direct: NAD+ Restore is a general wellness supplement, not a treatment for this condition, and it shouldn't be used as a substitute for medical care. If you're separately interested in cellular energy support once your care team is in the loop, here's what's in it.
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials
- 150 mg trans-resveratrol (Japanese Knotweed) + 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support
- 10 mg galactomannans from fenugreek — to support absorption
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
The bottom line: ME/CFS is one of the more directly studied conditions in NAD+-related research, with several real randomized trials — and the honest summary is genuinely mixed evidence, with the largest trial to date showing no clear benefit. That nuance matters more here than a simple yes or no.
References
- Forsyth LM, et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol. 1999;82(2):185-191.
- Castro-Marrero J, et al. Does Oral Coenzyme Q10 Plus NADH Supplementation Improve Fatigue and Biochemical Parameters in CFS? Antioxid Redox Signal. 2015;22(8):679-685. PMCID: PMC4346380.
- Castro-Marrero J, et al. Effect of Dietary CoQ10 Plus NADH Supplementation on Fatigue Perception and HRQoL in ME/CFS: RCT. Nutrients. 2021;13(8):2658. PMID: 34444817.
- Systematic review of randomized controlled trials for CFS/ME. PMCID: PMC6943902.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.